You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,096,757


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,096,757
Title: Method for treating proliferative diseases
Abstract:Methods are provided for treating proliferative diseases, especially cancers, comprising administering (1) a farnesyl protein transferase inhibitor in conjunction with (2) an antineoplastic agent and/or radiation therapy.
Inventor(s): Bishop; Walter R. (Pompton Plains, NJ), Catino; Joseph J. (Guilford, CT), Doll; Ronald J. (Maplewood, NJ), Ganguly; Ashit (Upper Montclair, NJ), Girijavallabhan; Viyyoor M. (Parsippany, NJ), Kirschimeier; Paul (Basking Ridge, NJ), Liu; Ming (Fanwood, NJ), Nielsen; Loretta L. (Millington, NJ), Cutler; David L. (Morristown, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:09/217,335
Patent Claims:1. A method of treating proliferative disease in a patient in need of such treatment, said treatment comprising administering, concurrently or sequentially, an effective amount of (1) the FPT inhibitor ##STR176## and (2) an antineoplastic agent and/or radiation therapy.

2. The method of claim 1 wherein said antineoplastic agent is selected from: Uracil mustard, Chlormethine, Cyclophosphamide, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Temozolomide, Methotrexate, 5-Fluorouracil, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Gemcitabine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Paclitaxel, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Interferons, Etoposide, Teniposide 17.alpha.-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Tamoxifen, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, Goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.

3. The method of claim 1 wherein said antineoplastic agent is selected from: Cyclophosphamide, 5-Fluorouracil, or Vincristine.

4. The method of claim 1 wherein said antineoplastic agent is Cyclophosphamide.

5. The method of claim 1 wherein said antineoplastic agent is 5-Fluorouracil.

6. The method of claim 1 wherein said antineoplastic agent is temozolomide.

7. The method of claim 1 wherein said proliferative disease is: lung cancer, pancreatic cancer, colon cancer, myeloid leukemia, melanoma, glioma, thyroid follicular cancer, bladder carcin-oma, myelodysplastic syndrome, breast cancer or prostate cancer.

8. The method of claim 1 wherein said FPT inhibitor, and said antineoplastic agent and/or radiation are administered concurrently.

9. The method of claim 1 wherein said FPT inhibitor, and said antineoplastic agent and/or radiation are administered simultaneously.

10. The method of claim 1 wherein said FPT inhibitor, and said antineoplastic agent and/or radiation are administered sequentially.

11. The method of claim 1 wherein said antineoplastic agent and/or radiation therapy is administered first.

12. The method of claim 1 wherein said FPT inhibitor is administered first.

13. A method of treating proliferative diseases in a patient in need of such treatment, said treatment comprising administering, concurrently or sequentially, an effective amount of (1) the FPT inhibitor ##STR177## and (2) gemcitabine.

14. The method of claim 13 wherein the proliferative disease is: prostate cancer, lung cancer, or pancreatic cancer.

15. The method of claim 13 wherein the proliferative disease is pancreatic cancer.

16. The method of claim 15 wherein the FPT inhibitor is administered orally in an amount of from 50 to 400 mg/day, and the gemcitabine is administered in an amount of from 750 to 1350 mg/m.sup.2 weekly for three out of four weeks.

17. A method of treating proliferative diseases in a patient in need of such treatment, said treatment comprising administering, concurrently or sequentially, an effective amount of (1) the FPT inhibitor ##STR178## and (2) a microtubule affecting agent.

18. The method of claim 17 wherein the microtubule affecting agent is paclitaxel or a paclitaxel derivative.

19. The method of claim 17 wherein the proliferative disease is prostate cancer.

20. The method of claim 17 wherein the proliferative disease is pancreatic cancer.

21. The method of claim 17 wherein the proliferative disease is lung cancer.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.